TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20394542
Drug: Topical anti-glaucoma
Normalized name: Anti Bac Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anti-glaucoma medications (AGM)
Study: 20394542
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no topical medications)
Study: 18588760
Drug: Local decongestant
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local decongestant
Study: 18588760
Drug: Vardenafil +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil + Local decongestant
Study: 15965687
Drug: Whole-body (18)F‐FDG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body (18)F‐FDG PET after one or two courses of induction chemotherapy (IC)
Study: 10520784
Drug: Abrupt cessation
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abrupt cessation of intravenous unfractionated heparin (UFH)
Study: 10520784
Drug: Intravenous weaning
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous weaning over 12 hours
Study: 10520784
Drug: Subcutaneous weaning
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous weaning over 12 hours
Study: 2115686
Drug: Insulin Novo
Normalized name: INSULIN NOVOLIN 70/30 INJ PEN 3ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin Novo Protaphan HM Penfill (100 IU/ml 'bed time') and 10 mg of glibenclamide in the morning (group A)
Study: 2115686
Drug: Insulin Novo
Normalized name: INSULIN NOVOLIN 70/30 INJ PEN 3ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin Novo Actraphan HM Penfill (100 IU/ml in the morning) combined with two 5 mg doses of glibenclamide at lunchtime and in the evening (group B)
Study: 29735813
Drug: L-tyrosine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tyrosine (100 mg/kg/day)
Study: 19564995
Drug: TIMER (Tool
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIMER (Tool to Improve Medications in the Elderly via Review)
Study: 15327641
Drug: Rinsing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rinsing with a sucrose solution
Study: 15327641
Drug: Rinsing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rinsing with water, a commercially available fluoride mouthrinse without antimicrobial agents, or brushing with a fluoride dentifrice
Study: 11194173
Drug: Soft gelatin
Normalized name: Norvir Soft Gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gelatin capsules containing 300 mg of alcoholic Hypericum extract (5% hyperforin and 0.3% hypericin)
Study: 11194173
Drug: Hard gelatin
Normalized name: Hard Gelatin Capsule Shell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hard gelatin capsules (standard formulation)
Study: 11194173
Drug: Soft gelatin
Normalized name: Norvir Soft Gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gelatin capsules
Study: 2442553
Drug: Lisinopril 40-80
Normalized name: lisinopril 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 40-80 mg/day
Study: 2442553
Drug: Metoprolol 100-200
Normalized name: metoprolol tartrate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100-200 mg/day
Study: 22236346
Drug: Chloroprocaine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroprocaine (40 mg) mixed with 12.5 μg of fentanyl
Study: 22236346
Drug: Lidocaine (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (35 mg) mixed with 12.5 μg of fentanyl
Study: 20350785
Drug: Meloxicam 7.5
Normalized name: meloxicam 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 7.5 mg orally twice per day starting on the day of implant
Study: 20350785
Drug: Meloxicam 7.5
Normalized name: meloxicam 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 7.5 mg orally twice per day starting 1 week prior to implant
Study: 8897116
Drug: Drug-free depressed
Normalized name: Malmea depressa bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free depressed patients
Study: 6615751
Drug: Topical antiprostaglandins
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antiprostaglandins
Study: 24403544
Drug: Hib conjugate
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hib conjugate vaccine booster
Study: 15319388
Drug: Assisted hatching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assisted hatching using acidic Tyrode's solution
Study: 11453889
Drug: Dihydroergotamine (DHE)
DrugBank: Dihydroergotamine (DB00320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dihydroergotamine (DHE) 0.5 mg
Study: 7798824
Drug: Coumadin (adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coumadin (adjusted dosage to maintain INR between 1.5-3)
Study: 7798824
Drug: Aspirin (fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (fixed dosage of 75 mg per day)
Study: 31816097
Drug: eIL-31-CuMVTT vaccine
Normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: eIL-31-CuMVTT vaccine (300 µg)
Study: 26554758
Drug: 15 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g/day of alcohol
Study: 26554758
Drug: 30 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g/day of alcohol
Study: 26554758
Drug: 0 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g/day of alcohol (control)
Study: 21613574
Drug: β‐AR blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: β‐AR blockade (intravenous propranolol)
Study: 18468672
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with 525 microg of venom monthly after a 6-week build-up period
Study: 12747499
Drug: DHEA 50
Normalized name: Natrol Mood & Stress DHEA 50mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 50 mg/day for 4 weeks
Study: 1552057
Drug: High-dose UVA1
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose UVA1 irradiation (130 joules/cm2)
Study: 1552057
Drug: High-dose UVA1
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose UVA1 irradiation
Study: 10068928
Drug: UVA-UVB therapy
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVA-UVB therapy
Study: 22149257
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of fluindione
Study: 22149257
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of acenocoumarol
Study: 18794727
Drug: PPARgamma agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPARgamma agonists (muraglitazar and other 10 PPARgamma agonists)
Study: 18794727
Drug: PPARgamma agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPARgamma agonists (one of three previously uncharacterized PPARgamma agonists)
Study: 12127877
Drug: Interleukin-2 as
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interleukin-2 as adjunctive therapy to antiretroviral therapy
Study: 10772563
Drug: Mixed administration
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed administration of DTPw-HBV and Hib vaccines
Study: 10772563
Drug: Separate administration
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate administration of DTPw-HBV and Hib vaccines
Study: 8545872
Drug: Steroid Withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid Withdrawal (SW) group
Study: 347884
Drug: Bromperidol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromperidol (1 mg tablets, initial dose: 1 mg, mean dose at end: 4.47 mg)
Study: 29331031
Drug: Bladder body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bladder body injection of 100U BoNT‐A in 10 mL saline
Study: 29331031
Drug: Trigonal injection
Normalized name: ERGONAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigonal injection of 100U BoNT‐A in 10 mL saline
Study: 26193635
Drug: Alefacept (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alefacept (two 12-week courses of 15 mg/wk i.m., separated by a 12-week pause)
Study: 23771104
Drug: BMS-986001 100
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-986001 100 mg
Study: 23771104
Drug: BMS-986001 200
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-986001 200 mg
Study: 23771104
Drug: BMS-986001 300
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-986001 300 mg
Study: 23771104
Drug: BMS-986001 600
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-986001 600 mg
Study: 10752802
Drug: Additional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional therapy with colloid and dobutamine (5 microg/kg/min then 10 microg/kg/min) for patients with pHi <7.35
Study: 10752802
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard resuscitation without additional therapy)
Study: 10752802
Drug: Additional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional therapy with colloid and dobutamine for patients with gastric mucosal pH of > or =7.35 at admission
Study: 10752802
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard resuscitation without additional therapy) for patients with gastric mucosal pH of > or =7.35 at admission
Study: 8694326
Drug: Epidural sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural sufentanil infusion at lumbar level (1 microgram/mL)
Study: 8694326
Drug: Epidural sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural sufentanil infusion at thoracic level (1 microgram/mL)
Study: 8694326
Drug: Epidural sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural sufentanil combined with bupivacaine at thoracic level (1 mg/mL)
Study: 6374885
Drug: Sclerotherapy (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sclerotherapy (20 ml Aethoxysclerol 1%)
Study: 24800998
Drug: FE 999049
Normalized name: Fe
DrugBank: Ferric cation (DB13949)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FE 999049 (recombinant follicle-stimulating hormone from human cell line)
Study: 20087375
Drug: Salba (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salba (0, 7, 15 or 24 g baked into white bread)
Study: 7856520
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (48-hour treatment)
Study: 28975821
Drug: Long-acting blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting blood cardioplegia (adenosine 12 mg via aortic root, followed by a single dose of long-acting solution at 14℃, 30 mL/kg)
Study: 28975821
Drug: St. Thomas'
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. Thomas' cardioplegia (initial 30 mL/kg at 14℃, followed by 15 mL/kg every 20 min)
Study: 21955930
Drug: Nicotine patches
Normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patches (experimental group)
Study: 21955930
Drug: No nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No nicotine patches (control group)
Study: 25338188
Drug: Concurrent feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent feedback
Study: 15080061
Drug: Intraprostatic injection
Normalized name: ALCOHOL 80 mL in 100 mL INTRAPROSTATIC LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraprostatic injection of Chuanshentong (6 ml mixed with lidocaine, once a day for 6 days)
Study: 15080061
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection containing lidocaine
Study: 2842137
Drug: Flumazenil (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (1.0 mg i.v.)
Study: 2842137
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia with midazolam and alfentanil
Study: 25635970
Drug: Prophylactic oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic oral, rectal or vaginal misoprostol
Study: 25635970
Drug: No-treatment option
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment option
Study: 20567999
Drug: ZP-PTH 20
Normalized name: PTH
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ZP-PTH 20 µg
Study: 20567999
Drug: ZP-PTH 30
Normalized name: PTH
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ZP-PTH 30 µg
Study: 20567999
Drug: ZP-PTH 40
Normalized name: PTH
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ZP-PTH 40 µg
Study: 20567999
Drug: FORTEO® injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: FORTEO® injection
Study: 16569219
Drug: scFOS 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: scFOS 2.5 g/d
Study: 16569219
Drug: scFOS 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: scFOS 5 g/d
Study: 16569219
Drug: scFOS 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: scFOS 7.5 g/d
Study: 16569219
Drug: scFOS 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: scFOS 10 g/d
Study: 16569219
Drug: scFOS (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: scFOS (all doses)
Study: 16569219
Drug: scFOS 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: scFOS 2.5 g/d and 5 g/d
Study: 12691651
Drug: Brånemark System
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brånemark System TiUnite surface implants
Study: 12691651
Drug: Brånemark System
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brånemark System machined-surface implants
Study: 11890519
Drug: Oral phentolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral phentolamine (Vasomax) 40 mg before sleep
Study: 9623694
Drug: Inspiratory flow
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory flow rate (V'I) at 30 L x min(‐1)
Study: 9623694
Drug: Inspiratory flow
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory flow rate (V'I) at 60 L x min(‐1)
Study: 9623694
Drug: Inspiratory flow
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory flow rate (V'I) at 90 L x min(‐1)
Study: 9623694
Drug: Inspiratory flow
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory flow rate (V'I) changes from 30 to 90 L x min(‐1)
Study: 27757553
Drug: Fosaprepitant 150
Normalized name: fosaprepitant 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosaprepitant 150 mg
Study: 25500485
Drug: New twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: New twice daily sustained-release (SR) paracetamol formulation (2 x 1,000 mg)
Study: 25500485
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) paracetamol (2 x 500 mg)
Study: 25500485
Drug: Extended-release (ER)
Normalized name: Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release (ER) paracetamol (2 x 665 mg)
Study: 19904268
Drug: RT‐5‐FU arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT‐5‐FU arm (5-fluorouracil 350 mg m(‐2) per day during radiotherapy)
Study: 19904268
Drug: RT‐GC arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT‐GC arm (gemcitabine 300 mg m(‐2) and cisplatin 30 mg m(‐2) on days 1, 8, 22, and 29)
Study: 19904268
Drug: RT‐GC+GC arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT‐GC+GC arm (same concurrent treatment followed by sequential full-dose gemcitabine 1000 mg m(‐2) and cisplatin 50 mg m(‐2) every 2 weeks)
Study: 15310642
Drug: Morphine PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine PCA plus a background infusion (group PCA-B)
Study: 15310642
Drug: Morphine PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine PCA alone (group PCA-A)
Study: 11123499
Drug: Paeoniae Radix
Normalized name: PAEONIA
DrugBank: Paeonia lactiflora root (DB16595)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paeoniae Radix (1.2 g extract powder once daily for 7 days) + 200 mg VPA on day 7
Study: 11123499
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg VPA gastro-resistant tablet alone on day 7
Study: 31738372
Drug: Minocycline 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 400 mg/d
Study: 19895780
Drug: Minocycline 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 200 mg/d
Study: 31738372
Drug: Combined Minocycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Minocycline (400 mg/d and 200 mg/d)
Study: 31738372
Drug: Minocycline 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 400 mg/d vs 200 mg/d
Study: 24024532
Drug: Fluoxetine or
Normalized name: fluoxetine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine or Venlafaxine
Study: 14641990
Drug: Gefitinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib (250 mg or 500 mg daily) in combination with carboplatin/paclitaxel
Study: 14641990
Drug: Gefitinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib (250 mg or 500 mg daily) in combination with cisplatin/gemcitabine
Study: 6336891
Drug: Orgotein (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orgotein (4 mg a week for six weeks)
Study: 6336891
Drug: Methylprednisolone acetate
Normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone acetate (4 mg a week for six weeks)
Study: 30617724
Drug: Sodium monensin
Normalized name: Monensin
DrugBank: Monensin (DB11430)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium monensin (MON; Rumensin® 200, Elanco Animal Health, Brazil) @ 0.6 mg/kg of body weight for 90 days
Study: 30047502
Drug: Conventional evidence-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional evidence-based therapy
Study: 21885990
Drug: Short-term statin
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term statin pretreatment (3-7 days) with atorvastatin (lipophilic statin)
Study: 15365307
Drug: Naltrexone (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (titrated to 50 mg/day)
Study: 15365307
Drug: Nalmefene (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene (titrated to 40 mg/day)
Study: 15365307
Drug: Alcohol (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.4 mg/kg for men, 0.34 mg/kg for women)
Study: 17944734
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (maintenance CNI dose)
Study: 17013995
Drug: Ibuprofen-arginine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen-arginine (400 mg)
Study: 6360786
Drug: 10-micrograms doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-micrograms doses of 15-R-15 methyl prostaglandin E2 for 24 h before treatment with aspirin
Study: 31120674
Drug: Vatinoxan (117-297
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vatinoxan (117-297 μg/kg)
Study: 26069949
Drug: Trivalent Inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent Inactivated Influenza Vaccine (TIV)
Study: 11844641
Drug: Glutamine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (80 mg/kg)
Study: 9671862
Drug: Alfuzosin, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin, 2.5 mg three times daily for 3 months, followed by maintenance of alfuzosin
Study: 9671862
Drug: Alfuzosin, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin, 2.5 mg three times daily for 3 months, followed by alfuzosin every other day
Study: 9671862
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of alfuzosin (no treatment)
Study: 28877729
Drug: Enhanced feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced feedback (monthly written feedback incorporating goal setting and action planning delivered by a senior clinical coordinator)
Study: 28877729
Drug: Standard feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard feedback (2‐monthly written feedback on multiple quality of pediatric care indicators)
Study: 27002696
Drug: Antiviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral therapy and surgical procedures
Study: 27002696
Drug: Dental treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental treatment, local and systemic keratoplastic formulations
Study: 20035590
Drug: Slow titration
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow titration schedule, 1.4 mg/kg/day
Study: 20035590
Drug: Slow titration
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow titration schedule, 0.8 mg/kg/day
Study: 20035590
Drug: Fast titration
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast titration schedule, 1.4 mg/kg/day
Study: 20035590
Drug: Fast titration
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast titration schedule, 0.8 mg/kg/day
Study: 20035590
Drug: Both maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both maintenance treatment groups (0.8 mg/kg/day and 1.4 mg/kg/day)
Study: 15162466
Drug: IL-2Rab (basiliximab)
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2Rab (basiliximab) 20 mg intravenously within 6 hours of graft reperfusion and on postoperative day 4
Study: 15162466
Drug: Steroid group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid group (standard immunosuppressive regimen with tacrolimus and corticosteroid), n = 49
Study: 8403178
Drug: Bupivacaine-lidocaine mixture,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine-lidocaine mixture, pH 6.7 with hyaluronidase (10 units.ml-1)
Study: 6752875
Drug: Pirprofen 800
Normalized name: Carprofen
DrugBank: Carprofen (DB00821)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pirprofen 800 mg/day